Combination Therapy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) and Eravacycline for Treating Elizabethkingia anophelis-Induced Pulmonary Infections: A Case Report
Qimei Wei,Wenxia Zuo,Rong Cong,Kun Luo,Shanshan Dong
DOI: https://doi.org/10.2147/idr.s490902
2024-11-04
Infection and Drug Resistance
Abstract:Qimei Wei, 1, &ast Wenxia Zuo, 2, &ast Rong Cong, 1 Kun Luo, 1 Shanshan Dong 1 1 Department of Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan, 430022, People's Republic of China; 2 Department of Cardiac Critical Care Medicine, Wuhan Asia Heart Hospital, Wuhan, 430022, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shanshan Dong, Department of Clinical Laboratory, Wuhan Asia Heart Hospital, No. 753 Jinghan Avenue, Jianghan District, Wuhan, 430022, People's Republic of China, Tel +86 18162516279, Email Elizabethkingia anophelis is an opportunistic pathogen that causes serious life-threatening infections. In this report, we describe a case of pulmonary infection caused by E. anophelis in a young female patient, following cardiac surgery, which was successfully treated with a combination of trimethoprim-sulfamethoxazole (TMP-SMZ) and eravacycline. Additionally, this report provides a summary of high-risk factors for E. anophelis infection, clinical manifestations, and therapeutic options. Given the high degree of antimicrobial drug resistance of the organism and the fact that inappropriate empirical antimicrobial therapy constitutes a risk factor for mortality, our case serves as a valuable reference for similar cases, highlighting potential strategies for effective management. Keywords: Elizabethkingia anophelis , pulmonary infections, trimethoprim-sulfamethoxazole, eravacycline In recent years, Elizabethkingia anophelis has gained global attention, as it has been recognized as an opportunistic pathogen that causes life-threatening nosocomial infections, particularly in immunosuppressed patients and those who are critically ill. Studies have indicated that the mortality rate of infections caused by E. anophelis is alarmingly high, ranging from 24% to 60%. 1,2 E. anophelis is a gram-negative bacillus known for its aerobic, non-fermentative metabolism of glucose. Its colonies typically appear smooth, light-yellow, and translucent. 3 Initially isolated from the midgut of Anopheles gambiae mosquitoes, E. anophelis has since been associated with nosocomial infections. 4 The spectrum of clinical manifestations of E. anophelis infection is broad, encompassing bacteremia, pneumonia, catheter-related bloodstream infection, meningitis, and skin and soft tissue infection, to name a few. 1,5 Interestingly, a significant majority of infections (80–87.5%) occur in hospital settings, specifically affecting patients with compromised immunity. 3,6 E. anophelis is a multidrug-resistant bacterium; however, its mechanism of resistance remains unclear. Studies have demonstrated that E. anophelis isolates are highly resistant to most β-lactams (including those with enzyme inhibitors), carbapenems, fluoroquinolones, and aminoglycosides. 6,7 The treatment of E. anophelis infections is challenging due to its intrinsic resistance to multiple antibiotics. Current therapeutic options are limited, and there is a lack of comprehensive clinical trials to guide effective treatment protocols. Reports have suggested successful treatment of E. anophelis infections with piperacillin-tazobactam. 8 Furthermore, vancomycin is considered a potential therapeutic option for meningitis caused by Elizabethkingia infections. 9 Some studies propose that minocycline may serve as a viable treatment for E. anophelis infections. 3 However, the efficacy of these antibiotics can vary depending on the site of infection and the susceptibility profile of the bacterial strain. In this report, we describe a case of pulmonary infection caused by E. anophelis in a post-cardiac surgery patient that was successfully managed with TMP-SMZ and eravacycline. A 29-year-old woman presented to Wuhan Asia Heart Hospital with severe shortness of breath and palpitations. The patient has a history of tetralogy of Fallot, for which she underwent corrective surgery 19 years ago. She achieved full recovery post-surgery, with normal growth and development, and no recurrence of cyanotic symptoms. However, five years ago, after contracting COVID-19, she began experiencing recurring chest tightness and palpitations, which went untreated. More recently, she experienced severe shortness of breath and palpitations, prompting her to seek medical attention. Upon admission, a transcardiac ultrasound revealed severe pulmonary and tricuspid regurgitations. Given the severity of her condition, surgical intervention was deemed necessary, and she underwent pulmonary valve replacement and tricuspid v -Abstract Truncated-
pharmacology & pharmacy,infectious diseases